Pfizer (PFE). Eli Lilly & Co. (NYSE:LLY) Report Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis

April 18, 2019 5:06 PM
Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced top-line results from a Phase 3 study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles